Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer

Shen, Jiajia; Yin, Qi; Chen, Lingli; Zhang, Zhiwen

doi:10.1016/j.biomaterials.2012.08.007

Cited by 132 publications

(97 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on this (P85-PEI)/TPGS nano-platform, Li's group developed two more nanosystems that co-delivered PTX/surviving shRNA and sorafenib/surviving shRNA for combination therapy of drug-resistant lung cancer and hepatocellular carcinoma, respectively. [74] Detailed in vitro and in vivo experiment results revealed that this (P85-PEI)/TPGS nano-platform served as a powerful and promising carrier for drug/gene co-delivery to treat cancers.…”

Section: Pei-based Nanoparticles With Other Nanostructuresmentioning

confidence: 99%

Co‐Delivery of Drugs and Genes Using Polymeric Nanoparticles for Synergistic Cancer Therapeutic Effects

Thambi

Lee

2017

Adv Healthcare Materials

103

View full text Add to dashboard Cite

Drug and gene delivery systems based on nanoparticles, microparticles and hydrogels have been widely studied for cancer treatment in the past decade. To achieve an efficient and safe delivery, selection of drug and gene delivery carrier is critical. Biocompatible polymeric nanoparticles are considerably promising carrier candidates in delivery of drugs and genes because of their unique chemical and physical properties. However, delivery of a drug or gene sometimes cannot achieve a satisfactory treatment effect. Therefore, co‐delivery of dual drugs or co‐delivery of a drug and a gene in a polymeric nanoparticle has attracted attention. Such co‐delivery systems can overcome multi‐drug resistance of chemical drugs and achieve a synergistic therapeutic effect. In this progress report, we summarize recent progress in the preparation and application of polymeric drug and gene co‐delivery nanosystems. The remaining challenges and future trends in this field are also included.

show abstract

Section: Pei-based Nanoparticles With Other Nanostructuresmentioning

confidence: 99%

Co‐Delivery of Drugs and Genes Using Polymeric Nanoparticles for Synergistic Cancer Therapeutic Effects

Thambi

Lee

2017

Adv Healthcare Materials

103

View full text Add to dashboard Cite

show abstract

“…21 It may be attributed to the tumor heterogeneity, complexity of drug resistance, and barriers of NPs circulating and crossing in vivo. 19,29,30 There are already substantial efforts to incorporate multiple functionalities and moieties within the nanoparticle design. The design for site-specific delivery of therapeutics will be considered in future such as inducing the targeting agent.…”

Section: In Vivo Antitumor Efficacymentioning

confidence: 99%

“…C-6 was selected as a model compound based on its high sensitivity of determination in the cell cytoplasm. 29 The sample wells were washed twice with PBS to remove the excess NPs that were not taken up by the cells. After fixing with 100 μL 4% paraformaldehyde for 15 minutes, the cells were washed twice again with cold PBS.…”

mentioning

confidence: 99%

A novel paclitaxel-loaded poly(D,L-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment

Ji¹,

Chen²,

Bao³

et al. 2016

IJN

View full text Add to dashboard Cite

Drug resistance has become a main obstacle for the effective treatment of lung cancer. To address this problem, a novel biocompatible nanoscale package, poly( d , l -lactide- co -glycolide)-Tween 80, was designed and synthesized to overcome paclitaxel (PTX) resistance in a PTX-resistant human lung cancer cell line. The poly( d , l -lactide-co-glycolide) (PLGA)-Tween 80 nanoparticles (NPs) could efficiently load PTX and release the drug gradually. There was an increased level of uptake of PLGA-Tween 80 in PTX-resistant lung cancer cell line A549/T, which achieved a significantly higher level of cytotoxicity than both PLGA NP formulation and Taxol ® . The in vivo antitumor efficacy also showed that PLGA-Tween 80 NP was more effective than Taxol ® , indicating that PLGA-Tween 80 copolymer was a promising carrier for PTX in resistant lung cancer.

show abstract

“…Increased G2/M phase arrest indicates the inhibition on cell division and restraint on cell growth. 38 The cell cycle of A2780 cells treated with various formulation of PTX was examined to evaluate the therapeutic effects of PTX. As seen from Figure 9, the G2/M phase treated with PTX-NP 5K for 24 hours was significantly increased to 70.8% compared with that of free PTX (43.7%).…”

Section: Cell Cycle Arrest Assaysmentioning

confidence: 99%

D-α-tocopherol polyethylene glycol succinate-based derivative nanoparticles as a novel carrier for paclitaxel delivery

Wu¹,

Chu²,

Tan³

et al. 2015

IJN

View full text Add to dashboard Cite

Paclitaxel (PTX) is one of the most effective antineoplastic drugs. Its current clinical administration Taxol ® is formulated in Cremophor EL, which causes serious side effects. Nanoparticles (NP) with lower systemic toxicity and enhanced therapeutic efficiency may be an alternative formulation of the Cremophor EL-based vehicle for PTX delivery. In this study, novel amphipathic 4-arm-PEG-TPGS derivatives, the conjugation of D-α-tocopherol polyethylene glycol succinate (TPGS) and 4-arm-polyethylene glycol (4-arm-PEG) with different molecular weights, have been successfully synthesized and used as carriers for the delivery of PTX. These 4-arm-PEG-TPGS derivatives were able to self-assemble to form uniform NP with PTX encapsulation. Among them, 4-arm-PEG 5K -TPGS NP exhibited the smallest particle size, highest drug-loading efficiency, negligible hemolysis rate, and high physiologic stability. Therefore, it was chosen for further in vitro and in vivo investigations. Facilitated by the effective uptake of the NP, the PTX-loaded 4-arm-PEG 5K -TPGS NP showed greater cytotoxicity compared with free PTX against human ovarian cancer (A2780), non-small cell lung cancer (A549), and breast adenocarcinoma cancer (MCF-7) cells, as well as a higher apoptotic rate and a more significant cell cycle arrest effect at the G2/M phase in A2780 cells. More importantly, PTX-loaded 4-arm-PEG 5K -TPGS NP resulted in a significantly improved tumor growth inhibitory effect in comparison to Taxol ® in S180 sarcoma-bearing mice models. This study suggested that 4-arm-PEG 5K -TPGS NP may have the potential as an anticancer drug delivery system.

show abstract

Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer

Cited by 132 publications

References 37 publications

Co‐Delivery of Drugs and Genes Using Polymeric Nanoparticles for Synergistic Cancer Therapeutic Effects

Co‐Delivery of Drugs and Genes Using Polymeric Nanoparticles for Synergistic Cancer Therapeutic Effects

A novel paclitaxel-loaded poly(D,L-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment

D-α-tocopherol polyethylene glycol succinate-based derivative nanoparticles as a novel carrier for paclitaxel delivery

Contact Info

Product

Resources

About

Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer

Cited by 132 publications

References 37 publications

Co‐Delivery of Drugs and Genes Using Polymeric Nanoparticles for Synergistic Cancer Therapeutic Effects

Co‐Delivery of Drugs and Genes Using Polymeric Nanoparticles for Synergistic Cancer Therapeutic Effects

A novel paclitaxel-loaded poly(D,L-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment

D-&alpha;-tocopherol polyethylene glycol succinate-based derivative nanoparticles as a novel carrier for paclitaxel delivery

Contact Info

Product

Resources

About

D-α-tocopherol polyethylene glycol succinate-based derivative nanoparticles as a novel carrier for paclitaxel delivery